TransMedics Group (NASDAQ:TMDX) Given New $130.00 Price Target at TD Cowen

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its target price increased by equities researchers at TD Cowen from $100.00 to $130.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the stock. TD Cowen's price objective points to a potential upside of 10.54% from the stock's current price.

TMDX has been the topic of several other reports. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $102.00 to $117.00 and gave the company a "buy" rating in a research report on Wednesday. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the company an "overweight" rating in a research note on Wednesday. Oppenheimer upped their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the company an "outperform" rating in a research note on Wednesday. Piper Sandler restated an "overweight" rating and issued a $120.00 price target (up from $95.00) on shares of TransMedics Group in a research note on Wednesday. Finally, Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $119.00.

TransMedics Group Stock Performance

NASDAQ TMDX traded up $23.47 on Wednesday, hitting $117.60. 4,939,623 shares of the stock were exchanged, compared to its average volume of 748,621. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The business's fifty day moving average is $83.85 and its 200 day moving average is $75.92. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $124.18. The company has a market capitalization of $3.85 billion, a PE ratio of -152.73 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. During the same period in the prior year, the firm posted ($0.08) earnings per share. The company's quarterly revenue was up 132.9% compared to the same quarter last year. Research analysts anticipate that TransMedics Group will post -0.14 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 12,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 12,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company's stock, valued at approximately $7,044,932.83. The disclosure for this sale can be found here. Insiders sold a total of 117,078 shares of company stock worth $9,972,971 in the last quarter. 6.70% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

Several large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its position in shares of TransMedics Group by 35.1% during the 1st quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company's stock worth $1,286,000 after buying an additional 4,518 shares during the period. Oak Ridge Investments LLC grew its position in shares of TransMedics Group by 59.5% during the 1st quarter. Oak Ridge Investments LLC now owns 18,267 shares of the company's stock worth $1,351,000 after buying an additional 6,813 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of TransMedics Group by 3.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company's stock worth $53,977,000 after buying an additional 21,737 shares during the period. Peregrine Capital Management LLC grew its position in shares of TransMedics Group by 9.6% during the 1st quarter. Peregrine Capital Management LLC now owns 75,267 shares of the company's stock worth $5,565,000 after buying an additional 6,580 shares during the period. Finally, SYSTM Wealth Solutions LLC grew its position in TransMedics Group by 5.3% in the 1st quarter. SYSTM Wealth Solutions LLC now owns 15,851 shares of the company's stock valued at $1,172,000 after purchasing an additional 801 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.